WaveMan
WaveMan · Company
ELDN · Eledon Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ELDN Eledon Pharmaceuticals (ELDN) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001404281
Quote by TradingView
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
114
13F, latest reported quarter

Eledon Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

No insider purchases or sales are on record for Eledon Pharmaceuticals, Inc. in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
BVF INC/IL
BUY
2024-05-13 SECtraded 2024-05-09
1,031,385
-
-5.6%
BVF INC/IL
BUY
2024-05-13 SECtraded 2024-05-09
821,121
-
-5.6%
BVF INC/IL
BUY
2024-05-13 SECtraded 2024-05-09
75,431
-
-5.6%
Biotechnology Value Trading Fund OS LP
BUY
2023-05-09 SECtraded 2023-05-05
837,146
-
-22.5%
Biotechnology Value Trading Fund OS LP
BUY
2023-05-09 SECtraded 2023-05-05
86,341
-
-22.5%
9 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
See all insider buying · insider selling
Showing the latest few. to see 4 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
114 funds bought in last quarter
more than 74% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
10.6% of the float short (float per yahoo 2026-10-27) · 10.2 days to cover · settled 2026-10-15
more than 71% of Pharma & Biotech
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch ELDN

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-32.8%12M
-58%-28%+2%+33%2025-102025-122026-022026-042026-062026-082026-10
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ELDN: institutional holders (13F)

13F holdings, latest reported quarter
BVF INC/IL
6,293,282 sh
$24.8M
BlackRock, Inc.
5,123,842 sh
$20.2M
Defilade Capital Management, L.P.
3,525,338 sh
$13.9M
VANGUARD CAPITAL MANAGEMENT LLC
3,417,223 sh
$13.5M
GOLDMAN SACHS GROUP INC
2,510,308 sh
$9.9M

Congress trades in ELDN

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ELDN planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ELDN mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
NVIT GS Small Cap Equity Insights Fund
$319.5K position · as of 2026-06-30
0.1%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$320.8K position · as of 2026-06-30
0.1%
Goldman Sachs Small Cap Growth Insights Fund
$437.9K position · as of 2026-07-31
0.1%
Goldman Sachs Small Cap Equity Insights Fund
$1.1M position · as of 2026-07-31
0.1%
Goldman Sachs Small Cap Value Insights Fund
$966.7K position · as of 2026-07-31
0.1%
iShares Micro-Cap ETF
$1.0M position · as of 2026-06-30
0.1%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 2
1 active
1
Phase 3
1 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$3.2M
-$315.0K
$1.6M
-34%
n/a
2024
$5.6M
$6.8M
$3.8M
+81%
n/a
2023
$2.6M
$404.6K
$1.4M
-21%
n/a
2022
$1.1M
-$2.0M
$1.1M
-48%
n/a
2021
$747.5K
-$4.8M
$2.1M
-71%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 114 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ELDN financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
n/a
capex not filed for the four quarters
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-236.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-72.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
n/a
capex not filed for the four quarters
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating incomen/an/a-$43.0M-$88.4M
Net income-$45.6M-$36.2M-$116.5M-$88.0M
EPS (diluted)-0.52-0.66-4.73-6.16
Operating cash flow-$62.3M-$47.3M-$39.5M-$28.4M
Cash$22.8M$20.5M$4.6M$56.4M
SEC XBRL, fiscal years, as known on 2026-10-28

ELDN Stock Sonar score 3/7 axes

Find similar shapesCompare

ELDN ranks highest on institutional and government (74th percentile) and risk and compliance (61st), and lowest on profitability (23rd), among Pharma & Biotech peers.

Profitability
23
Inputs
  • Return on equity-236.5% · 14 pct, sector of 545
  • Return on assets-72.7% · 32 pct, sector of 691
  • Return on invested capitalfewer than four consecutive quarters of operating income
  • Return on capital employedfewer than four consecutive quarters of operating income
Institutional and government
74
Inputs
  • Funds adding, latest quarter114 · 74 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
61
Inputs
  • Short interest, % of float+10.5% · 38 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.7% · 84 pct, sector of 511
4 not measured: Financial health, Growth, Insider conviction, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • Insider conviction needs 1 of 2 inputs, 0 present: no Form 4 purchase or sale (code P or S) in 180 days; no insider trades in 180 days
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

3 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies